Caveolae: Anchored, multifunctional platforms in the lipid ocean

Trends in Cell Biology

Volumn 13, Issue 2, 2003, Pages 92-100

  Van Deurs, Bo ^a   Roepstorff, Kirstine ^a   Hommelgaard, Anette M ^a   Sandvig, Kirsten ^b  

^a UNIVERSITY OF COPENHAGEN   (Denmark)

^b OSLO UNIVERSITY HOSPITAL   (Norway)

Author keywords

[No Author keywords available]

Indexed keywords

CAVEOLIN;

ANIMAL TISSUE; CARDIOVASCULAR SYSTEM; CAVEOLA; CELL MEMBRANE; CELL ORGANELLE; CELL TYPE; CHOLESTEROL TRANSPORT; LUNG; MOUSE; NONHUMAN; PRIORITY JOURNAL; REGULATORY MECHANISM; REVIEW; SIGNAL TRANSDUCTION;

ANIMALS; CAVEOLAE; CAVEOLIN 1; CAVEOLINS; CHOLESTEROL; ENDOCYTOSIS; HUMANS; MEMBRANE LIPIDS; MEMBRANE MICRODOMAINS; MICROFILAMENTS; PROTEIN TRANSPORT; SIGNAL TRANSDUCTION;

ANIMALIA;

EID: 0037306525     PISSN: 09628924     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0962-8924(02)00039-9     Document Type: Review

References (78)

1. Sandvig K., van Deurs B. Membrane traffic exploited by protein toxins. Annu. Rev. Cell Dev. Biol. 18:2002;1-24.
2. Thomsen P., et al. Caveolae are highly immobile plasma membrane microdomains, which are not involved in constitutive endocytic trafficking. Mol. Biol. Cell. 13:2002;238-250.
3. Pelkmans L., Helenius A. Endocytosis via caveolae. Traffic. 3:2002;311-320.
4. Nichols B.J. A distinct class of endosome mediates clathrin-independent endocytosis to the Golgi complex. Nat. Cell Biol. 4:2002;374-378.
5. Liu P., et al. Multiple functions of caveolin-1. J. Biol. Chem. 277:2002;41295-41298.
6. Le P.U., et al. Caveolin-1 is a negative regulator of caveolae-mediated endocytosis to the endoplasmic reticulum. J. Biol. Chem. 277:2002;3371-3379.
7. Sharma P., et al. Endocytosis of lipid rafts: an identity crisis. Semin. Cell Dev. Biol. 13:2002;205-214.
8. Johannes L., Lamaze C. Clathrin-dependent or not: is it still the question? Traffic. 3:2002;443-451.
9. Parton R.G. Ultrastructural localization of gangliosides; GM1 is concentrated in caveolae. J. Histochem. Cytochem. 42:1994;155-166.
10. Möbius V., et al. Intracellular distribution of a biotin-labeled ganglioside, GM1, by immunoelectron microscopy after endocytosis in fibroblasts. J. Histochem. Cytochem. 47:1999;1005-1014.
11. Orlandi P.A., Fishman P.H. Filipin-dependent inhibition of cholera toxin: evidence for toxin internalization and activation through caveolae-like domains. J. Cell Biol. 141:1998;905-915.
12. Shogomori H., Futerman A.H. Cholera toxin is found in detergent-insoluble rafts/domains at the cell surface of hippocampal neurons but is internalized via a raft-independent mechanism. J. Biol. Chem. 276:2001;9182-9188.
13. Torgersen M.L., et al. Internalization of cholera toxin by different endocytic mechanisms. J. Cell Sci. 114:2001;3737-3747.
14. Nichols B.J., et al. Rapid cycling of lipid raft markers between the cell surface and Golgi complex. J. Cell Biol. 153:2001;529-541.
15. Stahlhut M., van Deurs B. Identification of filamin as a novel ligand for caveolin-1: evidence for the organization of caveolin-1-associated membrane domains by the actin cytoskeleton. Mol. Biol. Cell. 11:2000;325-337.
16. Parton R.G., et al. Regulated internalization of caveolae. J. Cell Biol. 127:1994;1199-1215.
17. Pelkmans L., et al. Caveolar endocytosis of simian virus 40 reveals a new two-step vesicular transport pathway to the ER. Nat. Cell Biol. 3:2001;473-483.
18. Pelkmans L., et al. Local actin polymerization and dynamin recruitment in SV40-induced internalization of caveolae. Science. 296:2002;535-539.
19. Oh P., et al. Dynamin at the neck of caveolae mediates their budding to form transport vesicles by GTP-driven fusion from the plasma membrane of endothelium. J. Cell Biol. 141:1998;101-144.
20. Henley J.R., et al. Dynamin-mediated internalization of caveolae. J. Cell Biol. 141:1998;85-99.
21. Sever S., et al. Garrotes, springs, ratchets, and whips: putting dynamin models to the test. Traffic. 1:2000;385-392.
22. Merrifield C.J., et al. Imaging actin and dynamin recruitment during invagination of single clathrin-coated pits. Nat. Cell Biol. 4:2002;691-698.
23. Orth J.D., et al. The large GTPaes dynamin regulates actin comet formation and movement in living cells. Proc. Natl Acad. Sci. U.S.A. 99:2002;167-172.
24. Shin J.-S., et al. Involvement of cellular caveolae in bacterial entry into mast cells. Science. 289:2000;785-788.
25. Simionescu M., et al. Transcytosis of plasma macromolecules in endothelial cells: a cell biological survey. Microsc. Res. Tech. 57:2002;269-288.
26. Frøkjær-Jensen J. The plasmalemmal vesicular system in capillary endothelium. Conventional electron microscopic (EM) thin sections compared with the picture arising from ultrathin (ca. 140 Å) serial sections. Prog. Appl. Microcirc. 1:1983;17-34.
27. Frøkjær-Jensen J., et al. Three-dimensional organization of the plasmalemmal vesicular system in directly frozen capillaries of the rete mirabile in the swim bladder of the eel. Cell Tissue Res. 254:1988;17-24.
28. Bundgaard M., et al. The three-dimensional organization of plasmalemmal vesicular profiles in the endothelium of rat heart capillaries. Microvasc. Res. 25:1983;358-368.
29. Schnitzer J.E., et al. Endothelial caveolae have the molecular transport machinery for vesicle budding, docking, and fusion including VAMP, NSF, SNAP, annexins, and GTPases. J. Biol. Chem. 270:1995;14399-14404.
30. Predescu S.A., et al. Endothelial transcytotic machinery involves supramolecular protein-lipid complexes. Mol. Biol. Cell. 12:2001;1019-1033.
31. i-coupled Src kinase signaling pathway. J. Cell Biol. 150:2000;1057-1069.
32. Drab M., et al. Loss of caveolae, vascular dysfunction, and pulmonary defects in caveolin-1 gene-disrupted mice. Science. 293:2001;2449-2452.
33. Razani B., et al. Caveolin-1 null mice are viable but show evidence of hyperproliferative and vascular abnormalities. J. Biol. Chem. 276:2001;38121-38138.
34. Schubert W., et al. Microvascular hyper-permeability in caveolin-1 (-/-) knock-out mice: treatment with a specific NOS inhibitor, L-NAME, restores normal microvascular permeability in cav-1 null mice. J. Biol. Chem. 277:2002;40091-40098.
35. Goligorsky M.S., et al. Relationships between caveolae and eNOS: everything in proximity and the proximity of everything. Am. J. Physiol. 283:2002;F1-F10.
36. Bucci M., et al. In vivo delivery of the caveolin-1 scaffolding domain inhibits nitric oxide synthesis and reduces inflammation. Nat. Med. 6:2000;1362-1367.
37. Sowa G., et al. Distinction between signaling mechanisms in lipid rafts vs. caveolae. Proc. Natl Acad. Sci. U.S.A. 98:2001;14072-14077.
38. Isshiki M., Anderson R.G. Calcium signal transduction from caveolae. Cell Calcium. 26:1999;201-208.
39. Huang C.S., et al. Nerve growth factor signaling in caveolae-like domains at the plasma membrane. J. Biol. Chem. 274:1999;36707-36714.
40. Mineo C., et al. Regulated migration of epidermal growth factor receptor from caveolae. J. Biol. Chem. 274:1999;30636-30643.
41. Furuchi T., Anderson R.G.W. Cholesterol depletion of caveolae causes hyperactivation of extracellular signal-related kinase (ERK). J. Biol. Chem. 273:1998;21099-21104.
42. Li S., et al. Evidence for a regulated interaction between heterotrimeric G proteins and caveolin. J. Biol. Chem. 270:1995;15693-15701.
43. Song K.S., et al. Co-purification and direct interaction of Ras with caveolin, an integral membrane protein of caveolae microdomains. J. Biol. Chem. 271:1996;9690-9697.
44. Gustavsson J., et al. Localization of the insulin receptor in caveolae of adipocyte plasma membrane. FASEB J. 13:1999;1961-1971.
45. Parpal S., et al. Cholesterol depletion disrupts caveolae and insulin receptor signaling for metabolic control via insulin receptor substrate-1, but not for mitogen-activated protein kinase control. J. Biol. Chem. 276:2001;9670-9678.
46. Ringerike T., et al. Cholesterol is important in control of EGF receptor kinase activity but EGF receptors are not concentrated in caveolae. J. Cell Sci. 115:2002;1331-1340.
47. Roepstorff K., et al. Sequestration of EGF receptors in non-caveolar lipid rafts inhibits ligand binding. J. Biol. Chem. 277:2002;18954-18960.
48. Xiang Y., et al. Caveolar localization dictates physiologic signaling of beta2 adrenoceptors in neonatal cardiac myocytes. J. Biol. Chem. 277:2002;34280-34286.
49. Yamamoto M., et al. Caveolin is an activator of insulin receptor signaling. J. Biol. Chem. 273:1998;26962-26968.
50. Roy S., et al. Dominant-negative caveolin inhibits H-Ras function by disrupting cholesterol-rich plasma membrane domains. Nat. Cell Biol. 1:1999;98-105.
51. Pol A., et al. A caveolin dominant negative mutant associates with lipid bodies and induces intracellular cholesterol imbalance. J. Cell Biol. 152:2001;1057-1070.
52. Ikonen E., Parton R.G. Caveolins and cellular cholesterol balance. Traffic. 1:2000;212-217.
53. Fielding C.J., Fielding P.E. Caveolae and intracellular trafficking of cholesterol. Adv. Drug Deliv. Rev. 49:2001;251-264.
54. Sviridov D., et al. Apolipoprotein A-I stimulates the transport of intracellular cholesterol to cell-surface cholesterol-rich domains (caveolae). Biochem. J. 358:2001;79-86.
55. Graf G.A., et al. The class B, type I scavenger receptor promotes the selective uptake of high density lipoprotein cholesterol ethers into caveolae. J. Biol. Chem. 274:1999;12043-12048.
56. Smart E.J., et al. A role for caveolin in transport of cholesterol from endoplasmic reticulum to plasma membrane. J. Biol. Chem. 271:1996;29427-29435.
57. Razani B., et al. Caveolin-2-deficient mice show evidence of severe pulmonary dysfunction without disruption of caveolae. Mol. Cell. Biol. 22:2002;2329-2344.
58. Galbiati F., et al. Caveolin-3 null mice show a loss of caveolae, changes in the microdomain distribution of the dystrophin-glycoprotein complex, and T-tubule abnormalities. J. Biol. Chem. 276:2001;21425-21433.
59. Hagiwara Y., et al. Caveolin-3 deficiency causes muscle degeneration in mice. Hum. Mol. Genet. 9:2000;3047-3054.
60. Zhao Y., et al. Defects in caveolin-1 cause dilated cardiomyopathy and pulmonary hypertension in knockout mice. Proc. Natl Acad. Sci. U.S.A. 99:2002;11375-11380.
61. Lee H., et al. Caveolin-1 mutations (P132L and null) and the pathogenesis of breast cancer: caveolin-1 (P132L) behaves in a dominant-negative manner and caveolin-1 (-/-) null mice show mammary epithelial cell hyperplasia. Am. J. Pathol. 161:2002;1357-1369.
62. Galbiati F., et al. Caveolae and caveolin-3 in muscular dystrophy. Trends Mol. Med. 7:2001;435-441.
63. Minetti C., et al. Impairment of caveolae formation and T-system disorganization in human muscular dystrophy with caveolin-3 deficiency. Am. J. Pathol. 160:2002;265-270.
64. Parton R.G., et al. Caveolin-3 associates with developing T-tubules during muscle differentiation. J. Cell Biol. 136:1997;137-154.
65. Park D.S., et al. Caveolin-1/3 double-knockout mice are viable, but lack both muscle and non-muscle caveolae, and develop a severe cardiomyopathic phenotype. Am. J. Pathol. 160:2002;2207-2217.
66. Razani B., et al. Caveolin-1-deficient mice are lean, resistant to diet-induced obesity, and show hypertriglyceridemia with adipocyte abnormalities. J. Biol. Chem. 277:2002;8635-8647.
67. Smart E.J., et al. Caveolins, liquid-ordered domains, and signal transduction. Mol. Cell. Biol. 19:1999;7289-7304.
68. Bagnoli M., et al. Downmodulation of caveolin-1 expression in human ovarian carcinoma is directly related to alpha-folate receptor overexpression. Oncogene. 28:2000;4754-4763.
69. Bender F.C., et al. Caveolin-1 levels are down-regulated in human colon tumors, and ectopic expression of caveolin-1 in colon carcinoma cell lines reduces cell tumorigenicity. Cancer Res. 60:2000;5870-5878.
70. Racine C., et al. Reduction of caveolin-1 gene expression in lung carcinoma cell lines. Biochem. Biophys. Res. Commun. 255:1999;580-586.
71. Wiechen K., et al. Down-regulation of caveolin-1, a candidate tumor suppressor gene, in sarcomas. Am. J. Pathol. 158:2001;833-839.
72. Galbiati F., et al. Targeted downregulation of caveolin-1 is sufficient to drive cell transformation and hyperactivate the p42/44 MAP kinase cascade. EMBO J. 17:1998;6633-6648.
73. Engelman J.A., et al. Recombinant expression of caveolin-1 in oncogenically transformed cells abrogates anchorage-independent growth. J. Biol. Chem. 272:1997;16374-16381.
74. Fiucci G., et al. Caveolin-1 inhibits anchorage-independent growth, anoikis and invasiveness in MCF-7 human breast cancer cells. Oncogene. 21:2002;2365-2375.
75. Yang G., et al. Elevated expression of caveolin is associated with prostate and breast cancer. Clin. Cancer Res. 4:1998;1873-1880.
76. Yang G., et al. Caveolin-1 expression in clinically confined human prostate cancer: a novel prognostic marker. Cancer Res. 59:1999;5719-5723.
77. Lavie Y., et al. Upregulation of caveolin in multidrug resistant cancer cells: functional implications. Adv. Drug Deliv. Rev. 49:2001;317-323.
78. Lavie Y., Liscovitch M. Changes in lipid and protein constituents of rafts and caveolae in multidrug resistant cancer cells and their functional consequences. Glycoconjugates. 17:2000;253-259.